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Varying temporal criteria for generalized anxiety disorder:
prevalence and clinical characteristics in a young age
cohort
Abstract
BACKGROUND: This study questions the 6-month duration criterion for generalized anxiety
disorder (GAD) used in DSM-III-R and DSM-IV. METHOD: In adults from age 20/21 to 40/41
in the prospective Zurich Cohort Study, four groups of generalized anxiety syndromes defined
by varying duration (2 weeks, 1 month, 3 months and 6 months) were compared. RESULTS:
Applying DSM-III (1979-1999) and DSM-III-R (1986-1999) criteria, there were no significant
differences between the four groups in terms of family history of anxiety, work impairment,
distress, treatment rates or co-morbidity with major depressive episodes (MDEs), bipolar
disorder or suicide attempts. Only social impairment related to the length of episodes. The
6-month criterion of DSM-III-R and DSM-IV GAD would preclude this diagnosis in about half
of the subjects treated for generalized anxiety syndromes. CONCLUSIONS: In this
epidemiological sample, the 6-month duration criterion for GAD could not be confirmed as
clinically meaningful. GAD syndromes of varying duration form a continuum with
comparable clinical relevance.
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ABSTRACT
Background. This study questions the 6-month duration criterion for generalized anxiety disorder
(GAD) used in DSM-III-R and DSM-IV.
Method. In adults from age 20/21 to 40/41 in the prospective Zurich Cohort Study, four groups
of generalized anxiety syndromes defined by varying duration (2 weeks, 1 month, 3 months and
6 months) were compared.
Results. Applying DSM-III (1979–1999) and DSM-III-R (1986–1999) criteria, there were no sig-
nificant differences between the four groups in terms of family history of anxiety, work impairment,
distress, treatment rates or co-morbidity with major depressive episodes (MDEs), bipolar disorder
or suicide attempts. Only social impairment related to the length of episodes. The 6-month criterion
of DSM-III-R and DSM-IV GAD would preclude this diagnosis in about half of the subjects
treated for generalized anxiety syndromes.
Conclusions. In this epidemiological sample, the 6-month duration criterion for GAD could not be
confirmed as clinically meaningful. GAD syndromes of varying duration form a continuum with
comparable clinical relevance.
INTRODUCTION
Generalized anxiety disorder (GAD) with a
minimum duration of 2 weeks was first oper-
ationally defined in the Research Diagnostic
Criteria by Spitzer et al. (1978), in order to
separate GAD from panic disorder following
Klein’s observations (1964) of differential re-
sponses to drugs ; comprehensive historical re-
views of the conceptual development were
published by Blazer et al. (1991) and Rickels &
Rynn (2001a). From DSM-III (1980) through
DSM-III-R (1987) to DSM-IV (1993), the
definition of GAD underwent considerable
changes in the composition and number of re-
quired symptoms and their minimum duration
(from 1 month to 6 months). This extension
in length was mainly a consequence of concerns
about the co-morbidity of GAD with major
depression (Breier et al. 1985; Breslau, 1985;
Breslau & Davis, 1985; Brown et al. 1995, 1998;
Starcevic, 1995; Sartorius et al. 1996). However,
it is now well established that GAD and major
depression are often independent disorders
and their co-morbidity is not greater than
that of other disorders, as shown by data
from the National Comorbidity Survey (Kessler
et al. 1999; Kessler, 2000) and discussed in
the comprehensive review of Kessler et al.
(2001).
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Our longitudinal Zurich Cohort Study, with
six interviews from 1979 to 1999, had to cope
with all the DSM diagnostic changes. Assessing
anxiety not tailored to the changing diagnostic
concepts, we found, comparable to the de-
pression spectrum (Angst & Gamma, 2002a, b),
a wide spectrum of anxiety, from recurrent brief
anxiety states of a few days’ duration to longer-
lasting episodes of weeks and months (Angst &
Wicki, 1992). Well-founded serious doubt
about the value of the duration criterion of
GAD were expressed by Bienvenu et al. (1998)
on the basis of the Baltimore Epidemiologic
Catchment Area (ECA) Program; their data
demonstrated that the GAD syndrome of six
symptoms was clinically coherent but that
there were no differences between 1-month
and 6-month GAD in terms of co-morbidity
and demographic correlates. A recent paper
on the National Comorbidity Survey Repli-
cation in the USA (Kessler et al. 2005) also
found that maximum episode duration (1–2,
3–5, 6–11, o12 months) was unrelated to
most measures of impairment, co-morbidity
and sociodemographics. These results were in
line with those of an analysis by Maier et al.
(2000) of the ICD-10 criteria for GAD in
the large World Health Organization (WHO)
study on ‘Psychological Problems in Primary
Care’. Twin research showed that the fit of
models taking environmental and genetic fac-
tors into account did not differ whether GAD
was defined using a 1-month or a 6-month
minimum duration (Kendler et al. 1992). Fi-
nally, Rickels & Rynn (2001a) stressed in their
extensive historical review that it is not duration
of illness or excessive worry focus (Borkovec,
1994; Borkovec et al. 1991; Brown, 1997) but
the severity of anxiety symptoms that is most
relevant for the diagnosis and treatment of
GAD.
Assuming, in analogy to depression, the
existence of a spectrum of anxiety (Rickels &
Schweizer, 1997), from brief spells lasting a
few days to chronic severe manifestations, the
purpose of this paper was to compare general-
ized anxiety syndromes, defined by the symptom
criteria of DSM-III, DSM-III-R and DSM-IV
and varying duration (2 weeks, 1 month, 3
months and 6 months), and to present preva-
lence, clinical characteristics and clinical validity
of these four subgroups.
METHOD
Sample
The original Zurich study (A Prospective
Epidemiological Study of Depressive, Neurotic
and Psychosomatic Syndromes) identified a rep-
resentative sample of young adults in the Zurich
canton (population then 1.1 million) by ran-
domly selecting from all 19-year-old men as they
presented themselves for compulsory military
service (born 1959) and all women who were
20 years of age (born 1958). Details of sampling
procedures and refusal rates are presented in the
original publication (Angst et al. 1984).
The Zurich study involved a sample of 4547
subjects (2201 males, 2346 females) representa-
tive of the canton of Zurich in Switzerland, who
were screened in 1978 with the Symptom
Checklist 90-R (SCL-90-R; Derogatis, 1977), a
comprehensive self-report questionnaire of 90
questions that has been validated as a screening
instrument and covers a broad range of psychi-
atric symptoms.
To increase the probability of the development
of psychiatric syndromes, a stratified subsample
of 591 subjects (292 males, 299 females) was
selected for interview, with two-thirds consisting
of high scorers (above the 85th percentile) on
the Global Severity Index of the SCL-90-R, and
one-third consisting of a random sample of those
with lower scores. This stratified sample rep-
resents, weighted, 2600 persons of the same age
from the general population. The screening took
place in 1978, when the male participants were
19 and the females 20 years of age. Six interview
waves were conducted across 20 years from 1979
to 1999. There were no major differences in
sociodemographics between males and females.
The Structured Psychopathological Interview
and Rating of Social Consequences of Psychic
Disturbances for Epidemiology (SPIKE) was
administered (Angst et al. 1984). The SPIKE
assesses a series of somatic complaints, includ-
ing insomnia, headache, gastrointestinal, cardio-
vascular, respiratory, perimenstrual and sexual
syndromes. It also assesses depression, hypo-
mania, anxiety, phobias, obsessive-compulsive
symptoms, eating disorders, post-traumatic
stress disorder, substance abuse and suicidal
phenomena. Validity and reliability tests were
performed with particular reference to de-
pression and anxiety. All subjects were
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approached at each interview, irrespective of co-
operation with previous interviews, unless they
clearly specified that they did want not to be con-
tacted. The interviewers were mostly graduated
clinical psychologists and some psychiatrists
with special interview training. The inter-rater
reliability of the SPIKE was found to be high
with k values of 0.89 and 0.91 for the symptoms
of depression and anxiety (GAD) and 0.90 for
the corresponding syndromal diagnoses. Further
methodological details, including studies on val-
idity, have been published by Angst et al. (2005).
Across 20 years, 62.1% of the original sample
continued to participate in the study, and the
following proportions participated in specific
numbers of interviews : 47% in all six interviews;
63% in five; 74% in four; 82% in three; and
91.4% in at least two interviews. Those who
dropped out did not differ significantly from
those who stayed in follow-up interviews and
took part in the 1999 interview regarding strati-
fied sampling and most demographic character-
istics (Eich et al. 2003).
The Zurich study provides an unusual health-
care context. There are very few external con-
straints concerning the utilization of health-care
institutions. All inhabitants have insurance
coverage, with effectively free care (except with
psychotherapists not working under the super-
vision of a physician or a psychiatrist). There
are no waiting lists, and both primary and sec-
ondary care (e.g. psychotherapists and psy-
chiatrists) can be accessed directly; drug
prescribing is not centrally dictated or limited.
Diagnoses and clinical characteristics
DSM-III GAD could be diagnosed for all six
interviews (1979–1999), DSM-III-R GAD for
the last four interviews (1986–1999) and strict
DSM-IV criteria only for the last interview in
1999, due to changes in criteria developed and
published by the American Psychiatric Associ-
ation. In the 1993 interview, DSM-IV criterion
B for GAD (difficult to control the worry) was
not applicable yet, but criteria A and C were. We
therefore also tentatively diagnosed a DSM-IV
syndrome for this year. The duration of GAD
syndromes was subclassified into 2 weeks, 1
month, 3 months and 6 months in order to in-
vestigate the consequences of sharpening the
time criterion. A 2-week duration was chosen by
analogy with major depression. Briefer highly
recurrent episodes of DSM-III GAD syndromes
meeting the criterion of recurrent brief anxiety
(RBA; Angst & Wicki, 1992) were not included
in the GAD concept, because they were found to
be strongly associated with repeated panic
attacks. The symptoms were collected by the
interviewers over the past 12 months and by the
SCL-90-R (Derogatis, 1983) over the past
2 weeks. Only SCL-90-R symptoms with an
intensity over 2 (quite a bit or extremely) were
taken into account. Summarizing all six inter-
views, a hierarchical classification of GAD syn-
dromes was applied: 6 months>3 months>1
month>2 weeks.
Other psychiatric diagnoses were made ac-
cording to the most recent applicable DSM
version. Diagnoses were made by algorithms on
the basis of DSM-III criteria (panic disorder),
DSM-III-R criteria [major depressive disorder
(MDD), phobias, obsessive-compulsive disorder
(OCD)] and DSM-IV criteria (post-traumatic
stressdisorderandsubstanceabuse/dependence).
Bipolar-II disorder was defined by broad criteria
[major depressive episodes (MDEs) plus two of
seven symptoms of hypomania with a minimum
duration of 1 day]. Exclusion criteria were not
applied, in order to investigate the associations
between diagnostic categories. Adjustment dis-
orders were not diagnosed in our interview.
Age of onset was evaluated retrospectively
after having assessed the whole syndrome, and
was defined as the first manifestation of the
characteristic symptoms; these did not have to
qualify for the diagnosis.
Across all interviews, work and social impair-
ment as a consequence of anxiety were recorded
as present or absent, and distress was estimated
by an analogue scale (0–100). Treatment was
defined as professional treatment by anM.D. or a
psychologist andwas assessed separately for each
syndrome (e.g. depression, anxiety, panic, etc.)
for the past 12 months, for every year between
interviews and lifetime. Family history was as-
sessed using a list of all relatives, asking whether
they manifested a certain syndrome, illustrated
by stem questions and additional symptoms but
without the application of formal diagnostic cri-
teria ; relatives’ treatment was also assessed.
Statistics
Most analyses involved x2 tests applied to fre-
quencies and Kruskal–Wallis tests applied to
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continuous data. In addition, a classification tree
analysis was conducted to distinguish treated
from untreated cases, using a minimal number
of sequential binary decisions derived from a
variety of classifying or predictor variables.
These variables comprised the number of DSM-
III-R or DSM-IV anxiety symptoms, symptom
duration, symptom frequency, sex and risk group
used for sample stratification. The tree analysis
was used as one more way to assess the import-
ance of the duration criterion with regard to the
clinical severity of anxiety syndromes. STATA 8.2
(StataCorp., College Station, TX, USA) and
STATISTICA 6.0 (StatSoft Inc., Tulsa, OK, USA)
were used for data analysis.
RESULTS
Overlap of GAD concepts based on four
interviews (1986–1999)
Fig. 1 presents the overlap of 1-month GAD
syndromes for the last four interviews
(1986–1999), defined by DSM-III, DSM-III-R
andmodifiedDSM-IV criteria (without criterion
B). It demonstrates very strong associations
among the three concepts. DSM-III (105 cases)
was the broadest concept, embracing 61of 62
DSM-IV cases and 85 of 97 DSM-III-R cases.
The results show that DSM-IV syndromal cri-
teria for GAD are more restrictive than DSM-
III and DSM-III-R criteria. Because DSM-III
GAD criteria were applicable to all six inter-
views (1979–1999), we present a more extensive
analysis of them compared to DSM-III-R cri-
teria, which were applicable to interview waves
4–6 (1986–1999). Tentatively,we analysedDSM-
IV GAD in the same way (1986–1999), although
criterion B (worries) was not assessed in all in-
terviews.
Severity of GAD subgroups by duration and
diagnostic concept (1986–1999)
In Table 1, subjects with GAD, classified by the
three diagnostic versions of DSM and duration,
are presented with their total symptom scores as
measures of severity. It is impressive that neither
the temporal subgroups nor the diagnostic con-
cepts have great impact on the severity scores ;
from a clinical point of view the differences are
minor. It is notable that 2-week GAD was
overall as severe as 3-month GAD, while the
values of 1-month GAD tended to be lower and
those of 6-month GAD slightly higher.
Sociodemographic and clinical characteristics of
DSM-III GAD syndromes varying by duration
Table 2 compares the four DSM-III GAD syn-
dromes by minimum duration: 2 weeks, 1, 3 and
6 months. The four categories are hierarchical
and mutually exclusive. The cumulative preva-
lence rates varied between 2.5% (2 weeks) and
5.9% (1 month). The prevalence rate for all
DSM-III generalized anxiety syndromes with
a minimum duration of 2 weeks or more was
16.5%; only 3.2% of them lasted 6 months or
longer. Most potential validators did not dis-
tinguish between the four groups: sociodemo-
graphic variables, family history of anxiety,
work impairment, age of onset, distress, lifetime
treatment rates for anxiety and depression
and co-morbidity. The co-morbidity data dem-
onstrate that 2-week GAD was not more
associated with MDD or bipolar-II disorder
than 6-month GAD; in both cases the trend
was towards the opposite direction. Generally
6-month GAD tended to have higher co-
morbidity than 2-week GAD. Only social
impairment was positively related to the dur-
ation of DSM-III GAD (Table 2). A family
history of depression was exceptionally frequent
for 3-month GAD. It is remarkable that the
treatment rates for depression were especially
high in the categories of 3-month and 6-month
GAD and in general comparable to the treat-
ment rates for anxiety. With the exception of
20
DSM-III
DSM-III-R DSM-IV
24
61
0
0
1
11
FIG. 1. Venn diagram: longitudinal overlap of DSM generalized
anxiety disorder (GAD) concepts of 1 month’s duration.
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sociodemographic variables, the four GAD
groups differed significantly from the controls
without anxiety symptoms (n=203).
Clinical characteristics of DSM-III-R GAD
syndromes varying by duration
Very similar results were obtained on applying
the DSM-III-R definition of GAD to the four
groups varying by duration. We found that
4.5% of the population were identified as hav-
ing DSM-III-R GAD, 7.7% had 1-month
GAD, 6.2% 3-month GAD and 2% 2-week
GAD.
Table 3 gives a summary of some important
validators. Among the GAD groups, there were
no significant differences, whereas the GAD
groups differed significantly from the controls,
except for the sociodemographic variables. The
co-morbidity of GAD with MDE was indepen-
dent of the duration of the episodes ( p=0.99).
Again, the treatment rates for depression were
especially high in the categories of 3-month and
6-month GAD and comparable to the treatment
rates for anxiety. An analogous table for ap-
proximated DSM-IV GAD syndromes is not
presented because there was almost complete
overlap with DSM-III R GAD cases, and be-
cause criterion B of DSM-IV GAD could not be
assessed except in the 1999 interview.
Undiagnosed treated GAD cases
It is of great practical interest to determine the
number of patients with a GAD syndrome of at
least 2 weeks’ duration, who were treated pro-
fessionally by MDs or psychologists for gen-
eralized anxiety during the interview years but
did not meet DSM criteria for GAD. The DSM-
III concept missed only eight of 51 treated cases
(15%) across all six interviews because the dur-
ation of symptoms in these cases was less than
1 month. As a consequence of the 6-month cri-
terion, the DSM-III-R concept (applicable in the
last four interviews) missed 23 of 40 treated cases
(57.5%), and the DSM-IV concept (without
Table 1. Generalized anxiety disorder (GAD) DSM-III, DSM-III R, approx. DSM-IV
(1986–1999) and severity by sums of criterial symptoms
Duration 2 weeks 1 month 3 months 6 months p
DSM-III GAD
n 11 29 26 31
DSM-IV symptoms (6) 4.3 (0.19) 3.4 (0.28) 4.3 (0.26) 4.4 (0.28) 0.06
DSM-III-R symptoms (18) 13.1 (0.62) 11.7 (0.54) 13.3 (0.49) 13.9 (0.50) 0.02
DSM-III symptoms (29) 14.5 (1.5) 12.1 (1.0) 14.2 (1.2) 17.0 (1.1) 0.02
Tension 4.3 (0.56) 3.6 (0.40) 4.3 (0.35) 5.2 (0.30) 0.01
Autonomic symptoms 4.1 (0.74) 3.2 (0.45) 4.0 (0.58) 4.9 (0.62) 0.32
Expectation 2.7 (0.30) 2.7 (0.17) 2.5 (0.24) 3.2 (0.15) 0.10
Vigilance 3.5 (0.37) 2.7 (0.20) 3.4 (0.23) 3.7 (0.24) 0.02
DSM-III-R GAD
n 13 31 31 35
DSM-IV symptoms (6) 3.8 (0.39) 3.2 (0.30) 3.8 (0.31) 4.1 (0.28) 0.14
DSM-III-R symptoms (18) 12.3 (0.75) 11.5 (0.51) 12.6 (0.53) 13.4 (0.50) 0.05
DSM-III symptoms (29) 12.8 (1.8) 10.8 (1.1) 12.6 (1.2) 15.8 (1.1) 0.02
Tension 3.6 (0.65) 3.1 (0.40) 3.8 (0.37) 4.7 (0.34) 0.02
Autonomic symptoms 3.5 (0.76) 2.8 (0.45) 3.4 (0.53) 4.4 (0.60) 0.35
Expectation 2.4 (0.35) 2.4 (0.19) 2.4 (0.23) 3.1 (0.15) 0.04
Vigilance 3.3 (0.33) 2.5 (0.23) 3.0 (0.27) 3.5 (0.23) 0.03
DSM-IV GAD approx.
n 12 15 23 24
DSM-IV symptoms (6) 4.4 (0.23) 4.4 (0.25) 4.7 (0.25) 5.0 (0.19) 0.23
DSM-III-R symptoms (18) 13.5 (0.70) 13.1 (0.56) 13.9 (0.50) 14.6 (0.48) 0.20
DSM-III symptoms (29) 15.5 (1.7) 13.6 (1.3) 15.0 (1.3) 18.7 (1.2) 0.04
Tension 4.6 (0.60) 4.3 (0.47) 4.5 (0.38) 5.5 (0.37) 0.10
Autonomic symptoms 4.5 (0.79) 3.6 (0.67) 4.2 (0.63) 5.7 (0.72) 0.27
Expectation 2.8 (0.30) 2.7 (0.23) 2.7 (0.12) 3.3 (0.18) 0.24
Vigilance 3.6 (0.36) 3.1 (0.21) 3.6 (0.24) 4.3 (0.16) 0.01
Bonferroni threshold (21 tests) : p=0.0024.
Values are mean (S.E.).
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criterion B and applicable to the last two inter-
views) missed 13 of 27 treated cases (49%). In
the last interview, where the precise DSM-IV
diagnosis was possible, five of 10 treated cases
(50%) were missed; these all had a duration of
at least 1 month.
Table 4 shows that treatment rates steadily in-
creased with increasing numbers of DSM-III-R
orDSM-IV symptoms. Treatment also increased
when symptoms became more frequent. Dur-
ation of anxious episodes, however, had no
impact on treatment rates.
The tree analysis for treatment from 1986 to
1999 showed that the number ofDSM symptoms
alone was sufficient for optimal classification
of treated versus non-treated cases. A cut-off of
15.1 DSM-III-R symptoms or 5.5 DSM-IV
symptoms yielded optimal classification; this
suggests that treated participants were quite
symptomatic, on average. Duration of episodes
turned out to be the least important predictor of
treatment.
DISCUSSION
In this study a diagnosis of a generalized anxiety
syndrome was made on the basis of the symp-
toms only, independent of duration, in order to
test the consequences of a minimum duration of
6 months as required in DSM-III-R, DSM-IV
Table 2. DSM-III generalized anxiety disorder (GAD) syndromes (1979–1999)
Duration
DSM-III GAD syndromes
p Controlsa p2 weeks 1 month 3 months 6 months
Prevalence (%) 2.5 5.9 4.9 3.2 47.0
Males 0.6 6.4 3.4 2.5 58.1
Females 4.3 5.4 6.4 3.9 0.16 36.3 0.01
n 23 39 35 31 203
Parents married (%) 86.4 81.6 82.4 88.9 0.85 89.8 0.55
Education (%) 0.28 0.07
Lower 19.1 23.7 29.4 43.3 43.4
Medium 42.9 42.1 26.5 36.7 32.1
Higher 38.1 34.2 44.1 20.0 24.5
Urban/rural (%) 0.98 0.95
City 68.4 76.3 72.7 71.4 66.0
Town 10.5 5.3 6.1 10.7 10.8
Village 21.1 18.4 21.2 17.9 23.2
Parents’ income (Swiss francs/month) 0.52 0.25
<2000 4.4 2.6 14.3 20.0 7.3
2100–3000 34.8 35.9 28.6 26.7 36.7
3100–4000 17.4 15.4 20.0 20.0 25.7
>4000 43.5 46.2 37.1 33.3 30.4
Family history of
Anxiety 36.8 35.9 37.1 33.3 0.99 16.0 0.005
Depression 56.2 59.0 82.9 45.2 0.01 26.6 0.0005
Lifetime treatment for anxiety 52.2 51.3 60.0 71.0 0.36 4.4 0.0005
Treatment in interview years 34.8 35.9 34.3 54.8 0.28 0.0 0.0005
Lifetime treatment for depression 65.2 46.2 65.7 74.2 0.09 14.3 0.0005
Treatment in interview years 47.8 35.9 60.0 54.8 0.19 7.9 0.0005
Work impairment 91.3 69.2 82.9 83.9 0.16 0.0 0.0005
Social impairment 56.5 84.6 85.7 100.0 0.0005 0.0 0.0005
Any impairment 91.3 87.2 91.4 100.0 0.26 0.0 0.0005
Repeated panic attacks 30.4 28.2 31.4 48.4 0.30 2.0 0.0005
Major depressive episodes 43.5 56.4 57.1 58.1 0.70 14.8 0.0005
Major depressive disorder 13.0 25.6 28.6 22.6 0.57 10.8 0.02
Bipolar-II disorder 26.1 30.8 28.6 35.5 0.89 3.9 0.0005
Suicide attempts 30.4 25.6 11.4 38.7 0.08 3.9 0.0005
Age of onset (mean, S.E.) 15.3 (6.6) 15.7 (8.3) 16.2 (7.2) 13.2 (7.3) 0.32 14.7 (0.9) 0.21
Distress (mean, S.E.) 79.2 (4.1) 72.7 (3.2) 75.9 (3.3) 76.6 (4.0) 0.61 0 N.C.
Bonferroni threshold (42 tests) : p=0.0011.
N.C., not computable.
a Subjects without a diagnosis of GAD or recurrent brief anxiety (RBA).
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and ICD-10. We found a large number of cases
with a 1-month and 3-month duration and fewer
with a 2-week duration. Half of all patients
treated for a generalized anxiety syndrome de-
fined by DSM-III symptom criteria would not
be identified as having GAD using DSM-III-R
or DSM-IV criteria, mainly as a consequence of
the 6-month criterion. This finding is compat-
ible with the doubts about the utility of the
DSM-III-R and DSM-IV diagnostic constructs
expressed by Rickels and Rynn (2001a).
Generalized anxiety syndromes of shorter
duration (2 weeks, 1 month, 3 months), defined
by DSM-III and other DSM-III-R criteria, did
not differ significantly in a number of socio-
demographic and clinically relevant variables
from syndromes with a 6-month duration; for
instance, in severity, family history of anxiety,
phobias and depression, age of onset, work im-
pairment, distress or treatment rates. Symptom
duration without regard to diagnostic criteria
also showed no impact on treatment rates.
Furthermore, for optimal classification of
treatment cases in a tree analysis, symptom
duration was the least important classifier and
not needed for optimal classification. Only
social impairment increased with duration of
the DSM-III generalized anxiety syndrome,
but not if DSM-III-R criteria were applied.
Co-morbidity was also comparable across the
four groups; all psychiatric diagnoses assessed
were equally associated with GAD syndromes
of varying length, including MDEs. Thus, our
study confirms the results of Bienvenu et al.
Table 3. DSM-III-R generalized anxiety disorder (GAD) syndromes (1986–1999)
Duration
DSM-III-R GAD syndromes
p Controls p2 weeks 1 month 3 months 6 months
Prevalence total (%) 2.0 7.7 6.2 4.5 50.0
Males 1.4 7.0 5.0 3.1 58.3
Females 2.7 8.4 7.5 5.9 0.94 41.7 0.32
n 13 31 31 35 208
Parents married (%) 84.6 93.3 89.3 90.3 0.85 89.1 0.93
Education (%) 0.52 0.11
Lower 33.3 26.7 21.4 38.2 41.1
Medium 33.3 33.3 25.0 35.3 34.7
Higher 33.3 40.0 53.6 26.5 24.3
Urban/rural (%) 0.86 0.84
Large city 81.8 76.7 72.4 68.8 65.4
Small city 9.1 3.3 6.9 12.5 11.4
Town 9.1 20.0 20.7 18.8 23.2
Parents’ income (Swiss francs/month) 0.44 0.35
<2000 7.7 0 12.9 18.2 6.7
2100–3000 46.2 38.7 29.0 24.2 40.0
3100–4000 23.1 16.1 19.4 21.2 21.0
>4000 23.1 45.2 38.7 36.4 32.3
Family history of
Anxiety 25.0 35.5 25.8 32.4 0.82 20.3 0.28
Depression 69.2 58.1 71.0 45.7 0.17 41.8 0.009
Lifetime treatment for anxiety 30.8 45.2 61.3 62.9 0.14 12.0 0.0001
Treatment in interview years 30.8 32.3 29.0 48.6 0.34 2.4 0.0001
Lifetime treatment for depression 38.5 38.7 58.1 65.7 0.10 26.0 0.0005
Treatment in interview years 38.5 29.0 51.6 48.6 0.27 15.9 0.0005
Work impairment 76.9 61.3 77.4 80.0 0.33 20.7 0.0001
Social impairment 76.9 83.9 77.4 94.3 0.23 13.9 0.0001
Any impairment 84.6 83.9 83.9 94.3 0.52 21.6 0.0001
Repeated panic attacks 23.1 22.6 19.4 42.9 0.14 10.1 0.0001
Major depressive episodes 53.9 54.8 58.1 54.3 0.99 23.6 0.0001
Major depressive disorder 23.1 25.8 25.8 20.0 0.94 14.4 0.32
Bipolar-II disorder 23.1 29.0 32.3 34.3 0.89 8.7 0.0001
Suicide attempts 7.7 22.6 12.9 34.3 0.10 7.2 0.0001
Age of onset (mean, S.E.) 16.5 (5.9) 17.4 (8.9) 15.4 (8.0) 14.5 (8.0) 0.50 15.2 (0.6) 0.48
Distress (mean, S.E.) 70.8 (5.7) 69.0 (3.5) 71.6 (4.0) 76.0 (3.9) 0.36 57.5 (4.6) 0.08
Bonferroni threshold (42 tests) : p=0.0011.
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(1998) and Kessler et al. (2005) as well as our
earlier analysis (Angst, 1999).
Comparisons of GAD syndromes of 1-month
duration showed a great overlap among the
subjects meeting DSM-III, DSM-III-R and
modified DSM-IV definitions; this demon-
strates the stability of the GAD concept.
Two-week GAD cases (as originally defined
by the Research Diagnostic Criteria) compared
to 1-month cases showed equal or even slightly
higher distress, impairment and treatment rates.
The severity of anxiety is not dependent on
duration, as illustrated by panic attacks and re-
current brief anxiety of a few days’ duration.
Further studies will have to clarify the validity
of the 2-week definition of GAD in analogy to
major depression.
A problem not dealt with in this paper is the
difficulty of separating GAD syndromes from
depression; half of the cases met criteria for
MDEs but this association was independent of
the minimum duration of GAD syndromes. In
another paper we show prospectively the high
stability of mixed cases of anxiety and de-
pression (Merikangas et al. 2003).
We found a relatively high cumulative preva-
lence of GAD syndromes lasting 2 or more
weeks (16.5%). Our methods probably had
relatively high ‘sensitivity ’ in capturing these
syndromes because of repeated assessments,
which could minimize subjects’ tendencies to
forget episodes.
In conclusion, the data do not support the
restriction of the GAD construct to a minimum
duration of 6 months. Short and long episodes
form a continuum. The restricted definition of 6
months’ duration failed to identify 50% of
subjects treated professionally for generalized
anxiety syndromes, which is worrying if ‘ the
ultimate utility of diagnostic distinctions is to
guide treatment decisions ’ (Kessler & Wittchen,
2002). Shorter GAD syndromes did not differ in
onset and course from the 6-month cases.
Limitations
Readers may wonder why analyses of duration
involving DSM-III and DSM-III-R GAD cri-
teria are relevant at this time. That is, the DSM-
IV diagnosis ofGAD includes other new aspects,
such as a reduced list of possible associated
Table 4. Prevalence and treatment ratesa of anxiety symptoms and episodes (1986–1999)
Maximum number out of six DSM-IV anxiety symptoms
p1 2 3 4 5 6
Subjects 82 71 68 75 67 31
Prevalence (%) 16.6 13.0 11.7 7.6 6.9 2.0
% Treatment 3.7 11.3 20.6 34.7 41.8 71.0 0.0001
Maximum number out of 18 DSM-III-R anxiety symptoms
7 8 9 10 11–12 13–14 15+
Subjects 66 70 65 71 79 73 65
Prevalence (%) 22.4 16.7 16.0 13.8 14.7 10.9 5.6
% Treatment 1.5 2.9 9.2 12.7 24.1 46.6 52.3 0.0001
Maximum duration of anxious episodes
1–3 days <2 weeks 2+ weeks 1+ month 3+ months
Subjects 126 40 13 34 64
Prevalence (%) 45.2 13.2 4.4 16.7 20.6
% Treatment 34.1 45.0 30.8 32.4 39.1 0.70
Frequency of anxious episodes
1/year 2–3/year 4–11/year 1–2/month Weekly Daily
Subjects 35 29 37 57 60 55
Prevalence (%) 18.8 14.9 16.9 12.5 18.2 18.7
% Treatment 20.0 27.6 16.2 31.6 53.3 47.3 0.0001
a Treatment refers to the past 12 months prior to the interviews.
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symptoms (autonomic anxiety symptoms were
deleted from the list) and additional specifi-
cations regarding the nature of worry. We note
that changes from DSM-III-R to DSM-IV are
not without controversy. For example, although
patients with GAD in psychiatric clinics may not
frequently or reliably report autonomic anxiety
symptoms (Marten et al. 1993), patients with
GAD in primary care settings often do present
with these physical symptoms (Rickels & Rynn,
2001b). The DSM-IV focus on excessive worry,
and the nature of that worry, may also be of
limited clinical utility, especially in primary care
settings (Olfson et al. 1996; Rickels & Rynn,
2001b). Thus, the current diagnostic conception
of GAD appears to be an imperfect ‘moving
target ’. Nevertheless, our results are fairly con-
sistent across GAD definitions.
The sample size in the current study was rela-
tively small (although enriched by risk cases).
This was especially true for DSM-IV cases,
whereas the numbers of DSM-III and DSM-III-
R cases are more conclusive. Another limitation
is the attrition rate of 37.9%, discussed in more
detail elsewhere (Eich et al. 2003).
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